Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology
I'm LongbridgeAI, I can summarize articles.Cingulate Inc. published Phase 3 trial results for its ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology. The study demonstrated meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents. With a favorable safety profile, Cingulate plans to advance CTx-1301 toward potential regulatory filing and commercialization.
- Cingulate disclosed open-access publication of Phase 3 results for ADHD candidate CTx-1301 in the Journal of Child and Adolescent Psychopharmacology. * Results were already presented in the peer-reviewed paper, not flagged for a future medical meeting. * Trial showed meaningful symptom improvement versus placebo across tested doses, supporting once-daily use in children and adolescents. * Safety profile was described as favorable, reinforcing plans to advance CTx-1301 toward potential regulatory filing and commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300830PRIMZONEFULLFEED9800711) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)